Pro-Dex Inc (PDEX) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Pro-Dex Inc $33.97, price $71.94, upside -52.8%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Pro-Dex Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $13.16 – $73.41 · fair‑value band $19.12 – $44.16 · the $71.94 price screens above the $33.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.
Follow Pro-Dex in your weekly email
Every Wednesday you see whether Pro-Dex is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Show more
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Stock analysis
Pro-Dex Inc (PDEX) currently trades at $71.94, while our model-based Fair Value estimate is $33.97, implying the stock looks roughly 111.8% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $55.18 per share, and 1 of the 15 models we run sit above the $71.94 price.
Bear case: the Asset-Based group reads lowest at $7.69, and 14 of the 15 models stay below the price. Evidence for this calculation is medium.
Scenario range: $19.12 (bear) to $44.16 (bull), the price of $71.94 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Pro-Dex Inc reported revenue of $66.6M in FY2025 versus $42.0M in FY2021, a compound +12.2%/yr. Reported net income was $9.0M in FY2025, compounding +18.4%/yr from FY2021.
Key figures
Market cap $242M · P/E ratio 19.8 · P/S ratio 2.67 · EPS (TTM) $3.63 · Net margin 13.5% · Return on equity 29.8% · Return on assets (EBIT) 12.6% · Operating margin 15.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (medium confidence).
What moves the price
The share trades about 2% below its 52-week high and 201% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −53%, PDEX screens richer than that median.
Fair Value models
Bear $19.12Fair Value $33.97Bull $44.16
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($3.63 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+23.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
Start year 2020 (pandemic). Over 10 years: +17.4% a year
Revenue growth 38 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+9.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18% vs 30%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 16%
2025 sits 120% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside−53% · Bottom 25%
Profitability
Return on equity (TTM)30% · Top 25%
Return on assets10% · Top 25%
Net margin (TTM)16% · Top 25%
Operating margin (TTM)16% · Above median
Growth and dividend
Revenue growth15% · Above median
Balance sheet
Debt / equity0.25× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)19.8× · Cheaper than median
P/B6.60× · Priciest 25%
P/S (TTM)3.24× · Pricier than median
EV/EBITDA20.7× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)73· sector 31
PAST (return on equity)100· sector 25
HEALTH (low debt)87· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pro-Dex Inc Fair Value". https://www.fairvalue-calculator.com/stock/PDEX
Frequently asked questions
Is Pro-Dex Inc (PDEX) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $33.97 versus a price of $71.94, about −53% upside (overvalued).
What is the fair value of PDEX?
Our model-based fair value for Pro-Dex Inc is $33.97 (as of Sep 23, 2026), built from audited fundamentals. The current price: $71.94.
What is the quality score of PDEX?
Pro-Dex Inc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pro-Dex Inc (PDEX)?
Our model-based price target is the fair value of $33.97 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario $19.12, optimistic scenario $44.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Pro-Dex Inc stock forecast for 2026?
Our models put fair value at $33.97, about −53% upside versus a price of $71.94 (overvalued). Cautious scenario $19.12, optimistic scenario $44.16. The calculation is refreshed regularly with new filings.
What is the revenue of Pro-Dex Inc (PDEX)?
Pro-Dex Inc reported trailing-twelve-month revenue of about $74.6M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Pro-Dex Inc (PDEX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pro-Dex Inc it is $33.97 per share (as of Sep 23, 2026), against a price of $71.94. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Pro-Dex Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PDEX trades above its calculated fair value: price $71.94, fair value $33.97, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PDEX?
No. The price is what the market pays today ($71.94); the fair value is what the company's own numbers justify ($33.97). For Pro-Dex Inc the two are $37.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pro-Dex Inc worth?
The market values Pro-Dex Inc at about $242M (market capitalisation, as of Sep 23, 2026). Per share that is $71.94; our models calculate a fair value of $33.97 per share.
What do the bullish and bearish scenarios say about PDEX?
Our models span a range for Pro-Dex Inc: cautious scenario $19.12, base $33.97, optimistic $44.16 per share (as of Sep 23, 2026, price $71.94). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PDEX?
Pro-Dex Inc trades at a price-to-earnings ratio of 19.8 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $33.97 is built from several models across several years. Other multiples: P/B 6.6, P/S 3.2, EV/EBITDA 20.7.
How solid is the balance sheet of Pro-Dex Inc (PDEX)?
Balance-sheet figures for Pro-Dex Inc (as of Sep 23, 2026): return on equity 29.8%, debt of 0.25 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is PDEX from its 52-week high?
Pro-Dex Inc trades at $71.94, about 2% below its 52-week high of $73.41 and 201% above the low of $23.91 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $33.97 is for.
Which stocks are comparable to Pro-Dex Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pro-Dex Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $71.94, calculated fair value $33.97 (−53%), Quality Score 70/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PDEX calculated?
We run Pro-Dex Inc through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $33.97, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Pro-Dex Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pro-Dex Inc (PDEX)?
The closing price on Sep 23, 2026 was $71.94. Our model-based fair value is $33.97, about −53% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pro-Dex Inc right now?
A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case ($44.16). The favourable scenario is already priced in. A fairly wide model range ($19.12 to $44.16) leaves room in how you read the outcome.
Key figures of Pro-Dex Inc
How large is the market capitalisation of Pro-Dex Inc (PDEX)?
The market capitalisation of Pro-Dex Inc is $242M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pro-Dex Inc (PDEX)?
The price-to-sales ratio of Pro-Dex Inc is 2.67 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pro-Dex Inc (PDEX)?
Earnings per share at Pro-Dex Inc are $3.63 (price ÷ EPS = P/E 19.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pro-Dex Inc (PDEX)?
The net margin of Pro-Dex Inc is 13.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pro-Dex Inc (PDEX)?
The return on equity (ROE) of Pro-Dex Inc is 29.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pro-Dex Inc (PDEX)?
On an EBIT basis the return on assets of Pro-Dex Inc is 12.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pro-Dex Inc (PDEX)?
The operating margin of Pro-Dex Inc is 15.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pro-Dex Inc (PDEX)?
Revenue at Pro-Dex Inc is growing +14.6% versus a year earlier (3y avg +16.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pro-Dex Inc (PDEX)?
Earnings per share at Pro-Dex Inc are growing +22.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Pro-Dex Inc (PDEX) generate?
The free cash flow of Pro-Dex Inc is −$2.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pro-Dex Inc (PDEX) carry?
The net debt of Pro-Dex Inc is $16.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pro-Dex Inc in the live analysis
One click puts Pro-Dex Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 23, 2026